Lactiga is a venture-backed, NIH-funded biotherapeutics company developing patented biologics to treat and prevent mucosal infections with a focus on improving the quality of life in patients with Primary Immunodeficiency Diseases. They are unlocking the full therapeutic value of human milk antibodies to create the next-generation of anti-infectives that can battle even the world’s most dangerous pathogens including Covid. Lactiga has earned multiple awards, media attention (Globe & Mail, CTV, Toronto Star) and is participating in the On Deck Health (ODH2) cohort.
AngelMD Profile: https://www.angelmd.co/en/startups/lactiga
In this episode, we visit with Christopher Furmon who leads Vitro based in Colorado. Christopher doesn't come from a traditional biopharma track. Instead, he...
Mark Cherney is the Founder and Executive Chairman of both US Urology Partners and Prologics. This past year Mark transitioned from the CEO role...
